Evaluation of learning curve and safety aspects of phased radiofrequency ablation procedures for pulmonary vein isolation in atrial fibrillation by Martyrosian, Miran
SHORT THESIS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY (PhD)
Evaluation of learning curve and safety aspects of phased
radiofrequency ablation procedures for pulmonary vein
isolation in atrial fibrillation
Dr. Mihran Martirosyan MD
Supervisor: Prof. Dr. Zoltán Csanádi MD, PhD, DSc
University of Debrecen
Kálmán Laki Doctoral School
Debrecen, 2017
2Evaluation of learning curve and safety aspects of phased radiofrequency ablation
procedures for pulmonary vein isolation in atrial fibrillation
By Mihran Martyrosian, MD
Supervisor: Prof. Zoltán Csanádi MD, PhD, DSc
Doctoral School of Kálmán Laki Doctoral School, University of Debrecen
Head of the Examination Committee: Prof. Attila Tóth, PhD, DSc
Members of the Examination Committee: Prof. László Gellér, MD, PhD
Zoltán Szabó, MD, PhD
The Examination takes place at the library of Department of Cardiology, Faculty of Medicine,
University of Debrecen at 11 am on September 22nd, 2017.
Head of the Defense Committee: Prof. Attila Tóth, PhD, DSc
Reviewers: Attila Kardos, MD, PhD
István Lőrincz, MD, PhD
Members of the Defense Committee: Prof. László Gellér, MD, PhD
Zoltán Szabó, MD, PhD
The PhD Defense takes place at the Augusta Lecture Hall, University of Debrecen, at 1 pm on
September 22nd, 2017.
31. Summary
This work studied different aspects of phased radiofrequency ablation based on data from
a total of 159 patients who underwent the procedure for paroxysmal or persistent atrial
fibrillation. We demonstrated that the procedure is safe with no significant learning curve effect
only on fluoroscopy times, but not on complication rates, procedure time and acute isolation rate
of the pulmonary veins. In a subset of 27 patients the rate of silent cerebral ischemia (SCI) was
assessed by comparing the results of diffusion-weighted magnetic resonance imaging of the brain
before and after the ablation and correlated with the number of microemboli recorded during
different stages of the procedures using transcranial Doppler. New SCI on DW-MRI after PVI was
demonstrated in 6 patients (22%) with a tendency to disappear by the 3-month follow-up control
with the exception of one patient who still had a detectable lesion significantly reduced in size.
No significant difference in the total number of microemboli was detected in those patients who
demonstrated a new acute MRI lesion versus in those who had no new lesion. However, the
number of microemboli recorded during PV angiography was significantly higher in the patients
with versus in those without new brain lesions. Further, multivariate logistic regression results
demonstrated that the total MES count detected during the entire procedure was predictive of
silent cerebral lesions at an advanced age: patients aged 68 years or older were significantly more
likely, to have new brain lesions if the number of MESs was high.
Keywords: atrial fibrillation, phased radiofrequency ablation, transcranial Doppler recording,
diffusion-weighted magnetic resonance imaging
42. Introduction
2.1. Treatment strategies of atrial fibrillation and influence of learning curve on outcome of
pulmonary vein isolation
Catheter ablation (CA) for atrial fibrillation (AF) has emerged as an alternative to anti-
arrhythmic drug (AAD) therapy after the failure of at least one AAD, or even as the first line of
treatment in selected patients. Although a wide variety of ablation techniques have been used to
treat AF, it is generally agreed that the cornerstone of any transcatheter procedure is the
electrical isolation of all pulmonary veins (PVs). This is currently most commonly achieved by
encircling the PVs with focal radiofrequency (RF) lesions under the guidance of a 3-dimensional
electroanatomical mapping or navigation system. This point-by point ablation technique requires
extensive operator experience for efficiency and safety, and is usually associated with long
procedure times. Novel methods aiming at simpler and faster PV isolation (PVI) have therefore
been developed in recent years, including cryoballoon (CB) ablation and multipolar RF ablation
with the circular PV ablation catheter (PVAC). These single-shot techniques were designed to
create a circular ablation lesion around the PVs after the appropriate positioning of the ablation
catheter at the ostium or at the antra of each PV. A number of studies have demonstrated
comparable levels of success and safety profile, but shorter procedure times with these simplified
methods than with the conventional point- by- point ablation.
With the continuous increase in the number of AF ablation worldwide, the procedure is being
introduced into new and less experienced centers. Efficacy and periprocedural complications are
known to improve with experience in any invasive procedure including AF ablation although the
learning curve effect has not been extensively evaluated. Sairaku et al. have reported a
significantly higher incidence of procedure-related complications and a lower arrhythmia-free
survival at 6 months follow-up with the double Lasso catheter-guided encircling pulmonary vein
isolation in the first as compared with the following 156 patients who underwent the ablation.
Wojcik et al. have demonstrated a learning curve effect with CB ablation as indicated by the
decline in procedure and fluoroscopy times.
5However, no studies have been performed on the learning curve of the single-shot techniques
as assessed by procedural parameters and long-term efficacy.
2.2. Risk of microembolization during catheter ablation of atrial fibrillation
Clinically manifest stroke is one of the most feared complications of left atrial ablation for AF. In
experienced centers the rate of this complication is below 1% in these days. However, silent
cerebral ischemia (SCI) observed on diffusion-weighted magnetic resonance imaging (DW MRI) as
a complication of AF ablation has been reported at much higher rates and generated significant
concern regarding the long-term consequences of these procedures. The diagnosis of SCI is based
on the comparison of two cerebral DWI MR examinations, usually performed 48-72 hours apart
with the AF ablation procedure carried out between them. This imaging modality provides no
intra-procedural data which would suggest the mechanism of lesion formation. In contrast,
bilateral insonation of the middle cerebral artery (MCA) using transcranial doppler (TCD) offers a
real-time assessment of microembolization throughout the whole procedure. The use of TCD
during AF ablation was first reported by Kilicaslan, who found a significant relationship between
the number of microembolic signals (MESs) on TCD and clinical stroke events. Our group has
demonstrated that the majority of MESs are gaseous and the generation of microemboli is
concentrated in the phase of energy delivery with some ablation techniques. Further, the site of
ablation, the ongoing rhythm and certain biophysical parameters during phased RF ablation have
been found to be predictive of the rate of microembolization. No data are available on the
relationship between microembolization as measured with TCD during the ablation procedure
and silent cerebral ischemia as detected as a new ischemic lesion on DW MRI post-ablation.
2.3. Aim of our studies:
1. To investigate the time-dependent changes in procedure time and complication rates as a
function of operator experience with PVI using phased RF and the PVAC.
2. To study the learning curve of phased RF ablation on clinical efficacy as assessed by the 1-
year clinical outcome during initial experience with phased RF ablation.
63. To investigate the rate of microembolization during PVI and the incidence of new post-
ablation cerebral lesions on DW MRI in patients undergoing PVI with phased RF and the
PVAC.
4. To elucidate the potential relationship between the numbers of microemboli recorded
during the different phases of the left atrial ablation procedure with the PVAC and post-
ablation SCI.
3. Methods
The study was approved by the local ethics committee. All patients provided their signed
written informed consent prior to inclusion.
3.1. Patient selection for learning curve effect study
The study included consecutive patients who underwent PVI with phased RF ablation for
paroxysmal or persistent AF at our center between November 01, 2009 and April 30, 2012 and
who had regular follow-up during the first 12 months post-ablation. Exclusion criteria included
previous AF ablation, long-standing persistent AF, hyper- and hypothyroidism, significant valvular
heart disease, heart failure of NYHA class III or IV, a left ventricular (LV) ejection fraction ≤ 40%, a
left atrial (LA) diameter exceeding 50 mm, a LA thrombus, unstable angina or myocardial
infarction within the last 3 months, severe chronic obstructive pulmonary disease, known
bleeding disorders, contraindication to oral anticoagulation and pregnancy. All participating
patients signed the informed consent form prior to the procedure.
3.2. Patient selection for microembolization and silent cerebral ischemia study
Consecutive patients undergoing PVI with the PVAC and the GENius TM 14.4 RF generator for
symptomatic paroxysmal or persistent AF not adequately controlled by at least one anti-
arrhythmic drug were considered for enrollment in the study. The same exclusion criteria were
applied as for the learning curve effect study. All participating patients signed the informed
consent form prior to the procedure. In addition, all of them were asked to consent to
continuous, bilateral TCD detection during the ablation procedure, and to DW MRI examinations
7before and after PVI. Exclusion criteria including hyper- or hypothyroidism, heart failure, LA
diameter exceeding 50 mm and previous clinical ischemic stroke or transient is-chemic attack
(TIA) were applied. The study design conformed with the guiding principles of the Declaration of
Helsinki, and was approved by the Institutional Ethics Committee.
3.3. Patient preparation and preprocedural evaluation
Patients were admitted to the hospital 1 or 2 days prior to the procedure. Those on oral
anticoagulation with a vitamin K antagonist (VKA) continued to take the drug and the procedure
was performed with an international normalized ratio (INR) in the therapeutic range. For those
patients, who were not on VKA on admission to the hospital low molecular weight heparin was
started twice daily in a weight-adjusted dose and administered until 12 hours prior to the
procedure. All patients in the microembolization and SCI evaluation study were on uninterrupted
VKA treatment with INR between 2.0 and 3.0 on the morning of the procedure. All patients were
examined by transesophageal echocardiography within 24 hours prior to ablation to rule out an
intracardiac thrombus.
3.4. Ablation procedure with phased radiofrequency and the multielectrode pulmonary vein
ablation catheter
Ablation procedures were performed under conscious sedation with midazolam and fentanyl.
Decapolar (BARD Electrophysiology Inc., Lowell, MA, USA) and quadripolar (Woxx 4 J, 6F,
Biotronik, SE & Co. KG, Berlin, Germany) catheters were advanced from the femoral vein and
positioned into the coronary sinus and the right ventricle. Surface electrocardiograms and bipolar
intracardiac electrograms were registered with a Prucka, GE Medical digital recording system. A
single transseptal puncture was performed under fluoroscopic guidance, by a standard technique
using a Swartz SL (St. Jude Medical, Minnetonka, Mn, USA) transseptal sheath. This sheath was
then exchanged for a deflectable 12 Fr inner lumen CryoCath sheath (Medtronic CryoCath LP,
Kirkland, Quebec, Canada) to be used for guiding in left atrium under continuous flush with
heparinized saline. Immediately after the transseptal puncture, a 150 IU/kg body weight
intravenous (iv) heparin bolus was administered, followed by a continuous infusion to maintain a
minimum ACT target level of >300 s. during ablations. In the microembolization and SCI study a
8minimum ACT target of 350 s. was applied. Additional iv boluses of 2000-5000 IU heparin were
administered as needed to attain the minimum target ACT level. This heparinization scheme was
the same regardless the ongoing rhythm (sinus rhythm versus AF) during ablation. All PVs were
cannulated with a guidewire and the PVAC aiming at full electrical isolation which was confirmed
based on the signals recorded from the ostia of the PVs via the PVAC electrodes as described
below. Heparin was discontinued at the end of the procedure with no protamine sulphate
administered and the venous sheaths were removed 4-6 hours later or after a drop in the ACT
level below 150 sec. No electrical cardioversion had been performed during the procedure or in
the early post-ablation period before repeat cerebral MRI was completed in patients participating
in the SCI evaluation study.
3.5. Phased radiofrequency ablation system and the multielectrode pulmonary vein
ablation catheter
The circular multipolar PVAC was designed to create ostial or antral lesions of the PVs and
provide distal mapping and pacing to assess PVI. The version used in our studies consisted of a
25-mm helical electrode array with 10 platinum electrodes (3-mm electrode, 3-mm spacing, 25-
mm diameter), and over-the-wire tracking for enhanced PV targeting and placement stability. The
distal, circular segment of the catheter was perpendicular to the catheter shaft. Thermocouples
were placed as close as possible to the tissue interface for more accurate temperature
monitoring. The ablation catheter was advanced to the left atrium through the FlexCath sheath
and deployed in the antrum of each PV. The electrical conduction properties of the PV were
assessed on the basis of the signals recorded by the PVAC electrodes after placement inside the
ostium. Before the first RF delivery, the positions of the electrodes relative to the PV ostium were
always confirmed by means of a hand-held injection (8-10 ml) of contrast medium (Optiray,
Covidien Deutschland GmbH, Germany) diluted with saline in a 1:1 ratio through the FlexCath
sheath, which was positioned close to the anticipated PV ostium. The saline infusion used for
continuous flushing of the FlexCath sheath was interrupted for PV angiography and meticulous
care was taken to eliminate any air bubbles in the sheath and in the syringe before contrast
injections.
9The PVAC was connected to the GENius™ Multi-Channel RF Ablation Generator which contains 12
independently controlled RF generators for each electrode in the catheter. A unique feature of
the system is the duty-cycled phased RF energy, which is used for lesion formation via the PVAC.
It monitors the temperature on each electrode and adapts the power to achieve and maintain the
target temperature (nominally 60 °C). Power regulation is achieved through duty-cycling of the RF
energy, rather than voltage control. The time-period with no RF delivery, allows accurate
temperature monitoring and provides time for the electrode to cool between RF bursts. The
multi-electrode catheter design and the generator facilitate simultaneous bipolar (between the
electrodes) and unipolar (from the electrode to the ground pad) delivery of energy. Unipolar RF
delivery results in deeper lesions, while bipolar application facilitates lesions between electrodes.
The generator allows the operator to select between different ratios of simultaneous unipolar
and bipolar energy delivery including unipolar only, 1:1, 2:1, 4:1, or bipolar only. For example, the
4:1 energy mode indicates that 80% of the energy delivered is bipolar and the remaining 20% is
unipolar. The results of bench tests indicated that the depth of the lesions was proportional to
the energy mode selected, with unipolar delivery causing the deepest lesions, followed by 1:1,
2:1, 4:1 and bipolar RF application, the latter causing the shallowest lesions. The GENius™
monitors the power and the temperature on each electrode and displays to the operator when
the power and temperature are sufficient to create a good lesion (bars are in green color).
RF energy was applied outside the vein in the antral region, targeting potentials of high amplitude
on as many electrodes as possible for each application. Common ostia were isolated by inserting
the guide wire into the different side branches and ablating subsequent segments of the targeted
veins. For the initial applications, bipolar/unipolar RF delivery was usually started at a ratio of 4:1
for each PV and changed to a bipolar/unipolar proportion of 2:1 for a deeper lesion when a
sufficient reduction in local electrogram amplitude could not be achieved after multiple RF
deliveries. RF energy was applied for 60 s., usually 3-4 times per PV, until PVI was achieved. The
PV conduction was reassessed after each RF application with the electrodes being advanced
inside the ostium.
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3.6. Procedural modifications to reduce silent cerebral ischemia
As data on the relationship of SCI and some technical details of phased RF ablation became
available, important procedural modifications were recommended including the following:
1. Capturing the distal circular segment of the PVAC under saline before introduction into the
sheath to eliminate any microbubbles possibly entrapped between the electrode arrays.
2. It was demonstrated in animal studies, that simultaneous delivery to poles 1 and 10 may
result in a very high current density potentially leading to increased microembolus formation
when these electrodes get close to each other due to a squeezed position of the circular
segment of the catheter. Therefore, it was recommended to avoid simultaneous energization
of these electrodes.
3. It was recommended to perform all phased RF procedures on uninterrupted oral anti-
coagulation with a VKA with an INR value between 2-3 on the day of ablation. Further, non-
fractionated iv heparin should be administered to reach an ACT target above 350 sec.
These modifications were gradually incorporated into our practice and applied in all patients who
participated in the SCI evaluation study. Simultaneous RF deliveries to poles 1 and 10 were
allowed only after fluoroscopic assessment of their positions when the interelectrode distance
appeared at least twice the fixed distance between two other adjacent electrodes.
3.7. Transcranial doppler recording and evaluation
TCD recording was performed throughout the whole period of LA access. The transducer was
held in place by a proprietary headpiece supplied with the system. The MCAs were bi-laterally
insonated from transtemporal windows by using a multi-frequency doppler (Multi Dop T digital,
DWL, QL software 2.8) which insonates simultaneously with frequencies of 2 and 2,5MHz. The
system is capable of the automatic online identification of true MESs with a sensitivity of 100%
and specificity of 99.3% and also of discrimination between gaseous and solid emboli with a
specificity of 96.5%. TCD parameter settings as recommended by the consensus criteria were kept
constant during the procedures. The insonation depth was 45-55 mm, the sample volume was 8
mm, and the power was 60-100mW. MES counts were collected and evaluated separately during
the different stages of the procedure as follows:
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1. Transseptal puncture: the 30-sec. period after crossing the interatrial septum with the
transseptal needle.
2. PV angiography: contrast injection through the FlexCath transseptal sheath. MESs were
counted until they gradually decreased and disappeared after a marked burst, which usually
followed the bolus within 5-10 sec.
3. Energy delivery: from the start until 15 sec. after the termination of energy delivery.
4. The remainder of the procedure: that part of the LA access period during which none of the
aforementioned maneuvers were performed.
As bilateral recording was technically not possible in all patients, MES counts were calculated as
mean MES count per patient, using either the mean of the bilateral counts when both sides were
measured, or the unilateral data when only one side was available.
3.8. Cerebral magnetic resonance imaging
Cerebral MRI was performed the day before and within 48 hours after the procedure, using a
GE Sigma Excite 1.5 T (GE Medical Systems, Milwaukee, USA) scanner and an 8-channel phased
array head coil. A routine brain imaging protocol was performed, including anaxial diffusion-
weighted (DWI) single-shot spin echo echo-planar sequence [diffusion gradient b-values of 0 and
1000 s/mm2, repetition time (TR): 8700ms, echo time (TE): 104ms, slice thickness: 5 mm, matrix:
128x128], an axial T2-weighted fast spin echo (TR: 5640 TE: 95ms, slice thickness: 3 mm, matrix:
320x256), a sagittal T1-weighted spin echo (TR: 480ms, TE: 12ms, slice thickness: 3 mm, matrix:
256x160) and a coronal fluid attenuated inversion recovery (FLAIR) [TR: 8002ms, TE: 130ms, slice
thickness: 4 mm, matrix: 320x160] sequence. In addition, a 25 directions DTI sequence was
performed for advanced diffusion mapping.
DW MRI data were analyzed by two radiology experts blinded to the clinical status of the
patients. The pre-procedure MRI was compared with the post-procedure MRI to identify any new
procedure-related acute cerebral lesion defined as a focal hyper-intense area detected on the
DWI confirmed by apparent diffusion coefficient mapping to rule out a shine-through artifact. The
size and localization of focal diffusion abnormalities were analyzed. For patients, who were
positive for a new DWI lesion in the post-procedure MRI, another follow-up MRI was performed
3-month post-ablation.
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3.9. End points
The acute endpoint of the procedure was the electrical isolation of all PVs, as confirmed by an
entrance block evidenced by the disappearance of PV potentials in sinus rhythm (SR), during
coronary sinus pacing or during atrial fibrillation.
Long-term efficacy was defined as freedom from any atrial arrhythmia without a Class I or Class III
AAD after one procedure at 12 months follow-up with a blanking period in the first 3 months.
Significant peri-procedural complications were defined as any injury which resulted in death or
had long-term sequel, required an immediate intervention or prolonged hospital stay.
3.10. Follow-up
Patients were usually discharged within 2 days after the ablation. Following the procedure a
VKA was continued for at least 3 months. Patients taking an AAD before the procedure continued
the medication for 3 months post-ablation. It was then discontinued if the patient was free of an
AF relapse. VKA was discontinued 3 months after the ablation only in patients with a CHADS-VASC
score of 1 or below, while those patients with a higher stroke risk were kept on oral
anticoagulation regardless the results of postablation arrhythmia monitoring. Follow-up visits
were scheduled at 6 weeks, and 3, 6, 9 and 12 months post-procedure.
The 12-lead ECG was checked at each follow-up. Additionally, 24-hours holter monitoring was
performed at least twice, and also transtelephonic monitoring 3 times for 14- 21 days, during the
first 6 months. Patients were asked to transmit their rhythm at least 2-3 times a day, and always
in the event of any palpitation. During non-telemetry periods of follow-up, patients were
encouraged to visit the nearest hospital or outpatient facility to document their rhythm on an
ECG whenever they felt any abnormality of their heart beat. Arrhythmia recurrence was defined
as any atrial arrhythmia lasting for 30 sec. or longer. The definition of long-term success was
freedom from any atrial arrhythmia without any AAD, after one procedure with a blanking period
in the first 3 months.
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3.11. Statistical analysis
3.11.1. Statistical analysis for the learning curve study
For the learning curve effect study, the study period was divided into tierces to include the
same number of patients who underwent AF ablation within each tierce. Clinical characteristics,
procedural and follow-up data for subjects in each tierce were presented using numbers and
frequencies (%) for categorical variables and means with standard deviations (SD) for continuous
variables. Statistical calculations were performed with IBM SPSS Statistics 20 Software. The
distribution was examined with Kolmogorov-Smirnov test. Discrete variables were analyzed using
Chi-square test. ANOVA (Analysis of variances) and Kruskal-Wallis were used for comparisons of
groups. Cox regression as univariate test was used to estimate the hazard ratio. P value less than
0.05 was considered significant.
3.11.2. Statistical analysis for the microembolization and silent cerebral ischemia evaluation
study
For the microembolization and SCI evaluation study, complete data sets for all patients were
collected, including the results of intra-procedural TCD monitoring, pre- and post-ablation DW
MRI. Patient and procedural characteristics were evaluated by using means and standard
deviation (SD) or medians and interquartile range for continuous variables accordingly, and
counts and percentages for categorical variables. Groups of patients with and without DW MRI
lesions were descriptively compared in terms of MES counts using Wilcoxon Rank Sum test.
Logistic regression was used to evaluate the adjusted relationship between MES count and lesion
development. Age was used as an a priori adjustment factor. Other potential explanatory
variables were assessed for inclusion in the model. To improve distribution normality, age was
cubic transformed, and the total MES count per MCA was natural log transformed. As curvature
was observed in the relationship, a squared term for the log MES count was also used.
Interactions were detected between the log MES count and age cubed, and between the squared
log MES count and age cubed, and were therefore, included in the model. The effects of the MES
count were expressed by comparing the odds for lesion development at a MES count of 1500 (a
value close to the sample 75th percentile) to that at a count of 1100 (close to the sample median)
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in terms of odds ratios and 95% confidence intervals, specifically for levels across the range of age
within which lesion development was observed. Model checking was based on the Hosmer–
Lemeshow goodness of fit test.
4. Results
4.1. Results of learning curve study
A total of 132 patients were enrolled. Pre-ablation clinical characteristics of the first, second and
third 44 patients who underwent PVI with phased RF ablation are displayed. Significant
differences between the 3 tierces were found in the age and in the LA size only.
A total of 177 PVs were successfully isolated out of the 177 targeted in Tierce 1, while 173/176
and 169/171 in Tierces 2 and 3, respectively (p>0.05).
All PVs were successfully isolated in 44 (100%), 41 (93.8 %) and 42 (95.5 %) patients in Tierce 1, 2
and 3, respectively, (p=0.233). However, the number of RF applications (per PV) needed for
isolation demonstrated a significant decrease with experience (6.22 SD: 2.43; 4.65 SD: 1.32 and
4.12 SD: 1.2 in Tierce 1, 2 and 3, respectively; p<0.001). Procedure times demonstrated a trend
for lower values in Tierces 2 and 3 but the difference did not reach the level of statistical
significance. In contrast, a significant decrease in fluoroscopy times was demonstrated.
Pericardial tamponade requiring percutaneous subxiphoid drainage occurred in the 104th
consecutive patient (Tierce 3) as the only significant procedural complication.
Atrial arrhythmia-free survival rates without AAD at 12 months postablation were 68%, 75%, and
70.75% in Tierce 1, Tierce 2 and Tierce 3, respectively (p=0.772). On Cox proportional hazard
analysis which included clinical and procedural variables no significant predictor of arrhythmia
recurrence was demonstrated.
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4.2. Results of microembolization and silent cerebral ischemia study
4.2.1. Patient and procedural characteristics
A total of 36 consecutive patients who underwent PVI with the PVAC and the GENius 14.4
generator gave consent to pre- and post-ablation cerebral MRI and to intraprocedural TCD
monitoring. Two patients withdrew their consents from post-ablation MRI. TCD recording of
MESs with sufficient quality could not be achieved in 7, thereby the full data sets of 27 patients
were available for analysis.
A total of 108 PVs were successfully isolated. The mean (SD) procedure and fluoroscopy times
were 106 (27.1) and 23 (10) minutes, respectively. Procedural complications included 1 case of
pericardial tamponade which required pericardiocentesis. Clinical stroke did not occur in any of
the patients during or within 1 month after the ablation.
4.2.2. Transcranial doppler and magnetic resonance imaging results
The median (interquartile range) MES count per patient was 1151 (584). The highest rate of
microembolization in any stage of the procedure was recorded during RF delivery and the
majority of the MESs were gaseous during all phases of data collection.
New SCI on DW-MRI after PVI was demonstrated in 6 patients (22%): a single lesion in 2, two
lesions in 3, and three lesions in 1 case. The average (SD) lesion diameter was 7.05 (2.9) mm (4.1-
13.4 mm). The majority of these lesions had disappeared by the 3-month follow-up: 1 patient had
only a single lesion still detectable with a significant size reduction, and no new lesion as
compared with the post-ablation image was demonstrated in any patient.
Several clinical parameters were investigated as possible predictors for SCI, including age, gender,
LA diameter, LVEF%, CHA2DS2-VASC score, lacunary infarction on the pre-ablation MRI, the total
energy delivery time, the number of contrast injections during the procedure, the percentage of
concomitant use of E1/E10 and the mean intra-procedural ACT. There was no significant
difference among baseline clinical parameters between patients with and without new SCI.
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4.2.3. Association between microembolization and magnetic resonance imaging lesions
Comparative analysis between TCD and MRI results is shown. The total median MES count
(interquartile range) during the procedures among the patients who demonstrated new acute
MRI lesions was 1642.25 (912) as compared with 1019 (529) recorded in those who had no new
lesions, the difference did not reach the level of statistical significance at this patient cohort size
(p=0.129). However, the MES count per patient recorded during PV angiography was significantly
higher in the patients with versus those without new brain lesions: 257(249) vs 110 (71),
respectively (p=0.0009). Further, the multivariate logistic regression results demonstrated that
the total MES count detected during the entire procedure was predictive of silent cerebral lesions
at an advanced age: patients aged 68 years or older were significantly more likely, in a
progressive manner to acquire new brain lesions if the number of MESs was high.
5. Discussion
5.1. Learning curve study
Main findings
This study assessed the effects of learning curve on procedural parameters and long-term success
during phased RF ablation with the PVAC. Fluoroscopy time and the number of RF applications
required for successful PVI declined progressively with more experience, and a similar trend was
observed for procedure time. Importantly, no learning curve effect was demonstrated in the
success and complication rates. However, as the potential effect of experience on these
outcomes within one tierce, which consisted of 44 patients was not evaluated, this model is not
suitable to make a clear distinction between no learning curve effect or a steep learning curve.
Previous studies on learning curve in atrial fibrillation ablation
Although AF ablation is considered technically more challenging compared with other ablation
procedures, very limited data have been published on the significance of operator experience in
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relation to the safety and efficacy of the procedure. The first study that specifically addressed the
importance of the learning curve during AF ablation was published by Sairaku, who reported on
the results of the first 208 consecutive PVIs with point-by-point focal RF ablation in a medium-
volume center. A significant learning curve effect has not only been demonstrated in procedure
and fluoroscopy times, but also in complication rates and in the arrhythmia-free survival at 6-
month follow-up. In another study summarizing the experience, on 641 AF ablations at Johns
Hopkins Hospital complication rates were 9% during the first 100 and 4.3% during the subsequent
541 procedures. A worldwide survey and the most recent consensus statement on AF ablation
also suggest that safety and efficacy results are better in centers performing more than 100
procedures annually. These recommendations are largely based on the experience gained with
focal RF ablation.
Single-shot AF ablation techniques have been introduced to simplify and speed up PVI
procedures. Available data on the influence of operator experience as related to the safety and
efficacy results with these simplified approaches are also limited. Wójcik et al. reported on the
procedural experience gained over 8 years with CBA in a high-volume center. A continuous
decrease in fluoroscopy and procedure times was observed in each subsequent year and in
multivariate analysis both the year of procedure and the pre-ablation ALARMEc (Atrial fibrillation
type, LA size, Renal insufficiency, MEtabolic syndrome, cardiomyopathy) risk score were
independent predictors of procedure and fluoroscopy times. However, no significant decrease in
complication rate over the 8-year period has been demonstrated. The overall success rate at 12
months post-ablation was 73%, which improved with each subsequent year, however this was
related to the gradual fall in the ALARMEc risk score. In another single center study, the learning
curves for PVI with phased RF ablation vs. with the CardioFocus laser balloon have been
compared in the first 50 patients undergoing PVI with each technology. Procedure and
fluoroscopy times decreased with time in both technologies. Atrial arrhythmia recurrence 6
months after a single procedure improved significantly from the first tierce (31.2%) to the second
(17.6%) and to the third (0%) with CardioFocus laser balloon but no clear improvement was found
with phased RF ablation.
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These published data are in line with our results and suggest that the influence of operator
experience on clinical success and procedural complications of AF ablation may be less significant
with a single-shot as compared with the conventional method. This is further sup-ported by the
initial experience of a center with AF ablation. The first 109 patients at this center underwent PVI
with either 3-dimensional guided focal RF or with phased RF ablation. The 6-month success rate
was significantly higher with phased RF (68%) as compared with focal (39%) ablation, while
complication rates were similar. Procedure and fluoroscopy times were also significantly shorter
with phased RF ablation.
Although studies on direct comparison of PVAC with point-by-point PVI are limited, similar
success rates have recently been reported with the two techniques. In a multicenter prospective
randomized comparison, the arrhythmia-free survival at 12 months was 56% with wide-area
circumferential ablation and 60% with phased RF ablation in patients with paroxysmal AF. The
efficacy of PVI with the PVAC without any other LA ablation target in more chronic forms of AF is
yet to be determined. Although the TTOP-AF study evaluated phased RF ablation in such patient
cohort, other ablation catheters (multi-array ablation catheter and multi-array septal catheter) to
target low amplitude high frequency complex fractionated electrograms on the LA posterior wall
and septum were also used in that study.
The ongoing Victory-AF trial is currently enrolling patients with persistent and long-standing
persistent AF using PVAC GOLD the new generation of the PVAC catheter.
Potential implications for clinical practice
Available data suggest that the learning curve in PVI and the influence of previous operator
experience on relevant procedural and clinical endpoints might be ablation technology-
dependent. Ablation with a single-shot device can be performed not only with shorter procedure
and fluoroscopy times as compared with focal ablation, but also with more satisfactory clinical
outcome by a well-trained electrophysiologist who is proficient in transseptal catheterization and
LA ablation but is in the early phase of his AF ablation practice. Further, any of these simplified
approaches might be a reasonable choice for lower volume centers as a regular performance of a
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higher number of procedures is required not only to develop but also to maintain the adequate
technical skills with point-by-point ablation.
Limitations of the study
This study has several limitations. First, this was a single center, observational patient cohort
study including a relatively small number of patients thereby limiting the statistical power. There
was, however, no selection bias for the study as consecutive patients undergoing AF ablation with
phased RF were enrolled. Second, the main operator in all procedures had gained previous,
although limited experience with CBA before he started this study, which required somewhat
similar skills as ablation with the PVAC, therefore these results may not necessarily apply to what
could be achieved by someone with absolutely no experience in AF ablation. Third, although high
incidence of new silent cerebral ischemia detected by diffusion-weighted magnetic resonance
imaging was reported after phased RF ablations, this subclinical complication was not assessed in
this study. However, most recent data indicated a very substantial reduction in silent cerebral
embolization thanks to some technical and procedural modifications in phased RF ablation.
5.2. Silent cerebral ischemia evaluation study
As far as we are aware, this is the first study that has assessed the relationship between post-
ablation SCI on DW MRI and the number of microemboli detected by TCD during PVI. We
demonstrated a higher total MES count recorded during the overall LA access time in patients
with a new lesion on DW MRI (median: 1642 vs 1019) though the difference did not reach the
level of statistical significance at this limited number of patients with positive MRI findings.
Nonetheless, the relationship between the total MES count and SCI among the older patients was
significant, suggesting that not only the microembolic load to the brain, but also the status of the
cerebral vasculature might be relevant in lesion formation. Reduction of microembolus
generation to the lowest possible level therefore seems especially important in the elderly, and it
should be considered as far as selection of the ablation technique is concerned in this patient
cohort. Further, the additional risk of SCI has to be considered in these patients.
The MES count recorded during PV angiography proved to be a significant predictor of new
cerebral lesions in our study. As the number of microemboli recorded during PV angiography
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comprises only a relatively small fraction of the total MES count recorded throughout the entire
procedure, the strong correlation with SCI was somewhat unexpected. Although the majority are
gaseous, similarly to those recorded during other phases of the procedure, the physical
characteristics of MESs generated during contrast injections may differ. Moreover, PV
angiography involves the injection of rapid boluses of contrast material into the systemic
circulation, and the micro-emboli, although relatively small in numbers, are thereby, introduced
in a very short time. It may be speculated that, besides the number of microemboli, the intensity
of these microembolic showers reaching the brain circulation might also be an important
determinant of lesion formation.
Our results are in line with recent data published from the Mayo Clinic. In an elegant in vivo pig
model Takami et al. performed different catheter, sheath manipulations and ablations while
measuring microembolization using ICE, Carotid Doppler, and an extracorporeal circulation loop
which included a microbubble counter and blood filters to collect particles. Significant
microbubble formation was demonstrated on ICE, Carotid Doppler and in the loop during PV
angiography and sheath flushing at a high flow, while micro-particles were mostly found during
catheter dragging and after a steam pop. Our findings in patients seem to support these
experimental data and may well have important practical implications as around half of the
ablation centers worldwide routinely perform PV angiography during PVI.
Importantly, our definition of SCI was any new finding concerning the DW sequence with or
without FLAIR positivity. This is different from the definitions used in most other studies. We
chose this more sensitive criterion so as to be able to consider any detectable brain ischemia for
comparison with the MES data. FLAIR positivity was found in 5 of 6 patients and in 6 of 11 lesions
in our study, and the majority of the lesions had resolved by the 3-month follow-up
Although the aim of this research was to assess the relationship between TCD and DW MRI
findings and not to evaluate the safety of phased RF ablation, it is noteworthy that lower
incidences of SCI have been found in recent multicenter studies This favorable trend has been
attributed to procedural modifications of phased RF ablation based on the results of clinical and
preclinical studies. RF delivery to electrodes 1 and 10 getting close to each other due to a wedge
position of the PVAC loop has been identified as the most significant contributor to embolus
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generation due to a high current density, therefore simultaneous energization of these electrodes
was prohibited in these trials and electrode 10 even been removed from the novel PVAC Gold.
Concomitant RF application on poles 1 and 10 was however not a priori excluded in our study,
only when the interelectrode distance on fluoroscopy was considered unsafe. Nonetheless, this
more „liberal’’ practice did not contribute to a higher incidence of SCI lesions in our study.
The importance of SCI after AF ablation is still unclear. The concern that these lesions might be
related to a cognitive decline is supported by limited data. It has also been suggested that these
lesions might be viewed as surrogates for the clinical stroke risk and are useful for an assessment
of the risk involved with different ablation techniques and procedural changes. Our data suggest
that TCD detection during left atrial ablation might improve our understanding of the micro-
embolization process during these procedures.
6. New observations from our studies:
1. No learning curve effect as a function of operator experience was demonstrated during PVI
procedures using phased RF and the PVAC based on time dependent changes in procedure
time and complication rates, the acute success and the long-term arrhythmia-free survival.
2. A learning curve effect with phased RF ablation was demonstrated only in fluoroscopy times
and in the number of RF applications.
3. No significant difference in the total number of microemboli was detected in those patients
who demonstrated versus in those who did not new SCI on DW-MRI post-ablation.
4. Significantly higher number of microemboli were recorded during PV angiography in those
patients who demonstrated new SCI after the procedure.
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